Tables S1-3 and Figures S1-4 from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> Mutations
説明
<jats:p><p>Supplementary Table 1. IC50 values of Ba/F3 cells expressing common mutations in the presence or absence of the T790M to EGFR TKIs tested. Supplementary Table 2. IC50 values of Ba/F3 cells expressing uncommon mutations in the presence or absence of the T790M to EGFR TKIs tested. Supplementary Table 3. IC50 values of Ba/F3 cells expressing EGFR ins20 mutations to EGFR TKIs tested. Supplementary Figure 1. Western blot analysis showing the effects of increasing concentration of poziotinib, TAS6417, afatinib, or osimertinib, in NHEK-Neo cells. Supplementary Figure 2. TAS6417 exhibits slow-dissociation kinetics. Supplementary Figure 3. TAS6417 induces apoptosis in EGFR mutant cell lines but not in normal cells. Supplementary Figure 4. TAS6417 suppresses the growth of tumors driven by EGFR G719A+T790M.</p></jats:p>
